These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 20215482

  • 41. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec 17; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
    Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A.
    Target Oncol; 2014 Mar 17; 9(1):81-4. PubMed ID: 23283668
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
    Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M.
    Jpn J Clin Oncol; 2012 May 17; 42(5):442-6. PubMed ID: 22438405
    [Abstract] [Full Text] [Related]

  • 46. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug 17; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 47. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, Escudier B.
    Eur J Cancer; 2013 May 17; 49(8):1898-904. PubMed ID: 23490648
    [Abstract] [Full Text] [Related]

  • 48. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
    Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T.
    Minerva Urol Nefrol; 2010 Dec 17; 62(4):411-23. PubMed ID: 20944541
    [Abstract] [Full Text] [Related]

  • 49. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I, REACT Study Group.
    Eur J Cancer; 2012 Feb 17; 48(3):324-32. PubMed ID: 21803569
    [Abstract] [Full Text] [Related]

  • 50. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
    Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T, Nakatani T, Tomita Y, Azuma H, Yoshioka T, Tsujihata M, Uemura H.
    Jpn J Clin Oncol; 2013 Nov 17; 43(11):1132-8. PubMed ID: 23999768
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
    Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK.
    Eur J Cancer; 2012 Jul 17; 48(10):1519-24. PubMed ID: 22483544
    [Abstract] [Full Text] [Related]

  • 53. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
    Rodriguez-Pascual J, Cheng E, Maroto P, Duran I.
    Anticancer Drugs; 2010 Jun 17; 21(5):478-86. PubMed ID: 20401967
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
    Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B.
    Eur Urol; 2014 Apr 17; 65(4):713-20. PubMed ID: 23993162
    [Abstract] [Full Text] [Related]

  • 57. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V.
    Urology; 2013 Jan 17; 81(1):143-9. PubMed ID: 23273080
    [Abstract] [Full Text] [Related]

  • 58. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Amato RJ, Flaherty AL, Stepankiw M.
    Clin Genitourin Cancer; 2012 Mar 17; 10(1):26-31. PubMed ID: 22169794
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM.
    Clin Genitourin Cancer; 2007 Sep 17; 5(6):359-61. PubMed ID: 17956708
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.